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Abstract
Background: Perceived Health Related Quality of Life (HRQoL) is impaired in obstructive sleep apnea (OSA). This
study examines changes in HRQoL aspects occurring immediately after CPAP titration. Furthermore, we analyzed
variations in each gender and in patients undergoing home or laboratory-based CPAP titration pathways.
Methods: Twohundredfive outpatients (151 M) (56.7 ± 10.3 years) were evaluated, before first visit and nocturnal
diagnostic examination (T0), and the morning after CPAP titration (T1). Two self-reported HRQoL questionnaires
were administered: Psychological General Well-Being Index (PGWBI), composed by six subscales, and 12-Item Short-
Form Health Survey (SF-12), including Physical (PCS) and Mental Component Summaries (MCS). CPAP titration was
performed using auto-adjusting CPAP units at patients’ home or in the sleep laboratory.
Results: PGWBI scores at T1 improved compared to T0 (p < 0.0001). A similar improvement was observed in SF-12
MCS (p = 0.0011), but not in SF-12 PCS. Changes were independent from anthropometric parameters, OSA severity
and excessive daytime sleepiness. Gender comparisons showed better HRQoL in males at both times. At T0,
patients who received home or laboratory CPAP titration pathways did not show any differences in PGWBI
and SF-12 scores. At T1, PGWBI and SF-12 MCS improved in both home and laboratory groups.
Conclusions: This study gives evidence that first time CPAP application for titration can lead to a general
increase in perceived well-being. Gender comparisons showed better perceived HRQoL with more subscales
improvements in males after CPAP titration. The improvement was similar with both home and laboratory
CPAP titration pathways.
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Background
Obstructive sleep apnea (OSA) is a common disorder
characterized by repetitive episodes of complete (apnea)
or partial (hypopnea) upper airway obstruction during
sleep, associated with ongoing increasing respiratory
efforts, intermittent hypoxia, systemic and pulmonary
arterial blood pressure fluctuations and sleep disruption.
Approximately 9% of females and 24% of men in the
general population have OSA [1] and most remain
undiagnosed.
OSA patients may exhibit several typical symptoms
including habitual snoring (often disruptive for bed
partners), feeling of unrefreshed awaking, headache, neu-
rocognitive deficit, fatigue, excessive daytime sleepiness
(EDS). These symptoms have often a significant impact
on health-related quality of life (HRQoL) including its
social and psychological domains [2–6].
There is a number of effective treatment options for
OSA (including lifestyle advice, mandibular splint
devices, surgery, etc.); however, the current most widely
prescribed therapy for patients with moderate-severe
OSA or mild OSA with comorbidities is nocturnal
continuous positive airway pressure (CPAP). CPAP is
usually set at a pressure sufficient to prevent upper air-
way collapse in all body positions and sleep stages. CPAP
titration is determined by an attended overnight CPAP
titration study with full polysomnographic (PSG)
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monitoring in a sleep laboratory, or by automatic posi-
tive airway pressure (APAP) devices [7–9].
OSA treatment with CPAP has shown to improve
HRQoL [6]. However the initial impact of CPAP on
many aspects related to HRQoL like mood, psycho-
logical well-being, self-control, energy, mental and phys-
ical health and fatigue have not been investigated.
Aim of this study was to evaluate the immediate effect
of CPAP administration on self-perceived HRQoL in
OSA patients referred to a laboratory for sleep related
breathing disorders. Furthermore, we analyzed HRQoL-
related variations in each gender and in patients under-
going home or laboratory CPAP titration pathways. We
have already evaluated the HRQoL of patients at the first
time visit [10], and after diagnosis disclosure [11]. What
makes this trial unique and distinguishes it from other
such studies is that, as far as we know, for the first time
it examines the immediate effect of CPAP on perceived
well-being.
Methods
We performed a study involving patients afferent to our
Sleep Laboratory for respiratory disorders during sleep.
Out of 1067 consecutive outpatients, 205 completed the
study (54 F, 151 M), age 25–79 years (56.7 ± 10.3).
This was a prospective observational study. All CPAP-
naïve patients with a new diagnosis of OSA were eligible
to be included in this study.
The exclusion criteria were: refusal to participate,
refusal of CPAP therapy, central sleep apnoea syn-
dromes, obesity hypoventilation syndrome, restrictive
pulmonary and restrictive chest wall diseases, severe
congestive heart failure, a history of life-threatening
arrhythmias, severe cardiomyopathy, long-term oxygen
therapy, drug or alcohol abuse, severe cognitive impair-
ment, concurrent oncological diseases, and a history of
narcolepsy or restless legs syndrome. Patients affected
by psychiatric or neurological disease were also
excluded, as well as subjects taking neurological medica-
tion. Patients with a prior diagnosis or treatment for
OSA were excluded (n. 252), as were subjects who did
not complete full diagnostic and CPAP titration process
or questionnaires (n. 605) (Fig. 1).
Subjects underwent a detailed clinical evaluation that
included sleep-related disorders. Institutional Ethical
Committee approved the protocol (Palermo I AOUP “P.
Giaccone”, report no 8/2014) and all subjects gave their
written informed consent for personal data processing.
Nocturnal monitoring was performed with a portable
computerized system (Somté or Somnea Compumedics
Inc.; Abbotsford, VIC, Australia). The recorded signals
were airflow, snoring, thoracic and abdominal move-
ments, limb movements, body position, arterial oxygen
saturation, pulse rate, and pulse waveform. Duration of
recordings was at least 6 h. Apneas and hypopneas were
visually scored and OSA severity defined according to
American Academy of Sleep Medicine standard criteria
[12]. Percent study-time with O2 saturation <90%
(TSat90) was evaluated.
Questionnaires
The Psychological General Well-Being Index (PGWBI)
was used to measure perceived psychological well-being.
The responses to 22 questions are arranged in six sub-
scales: Anxiety, Depression, Well-being, Self-control,
Health and Vitality. Item responses are rated on a six-
point Likert scale ranging from 0 to 5. Higher scores in-
dicate better well-being. The subscales sum provides a
global index score for subjective well-being (range 0–
110). Considering “distress” as the reverse of well-being,
a global score <60 suggests a “Severe Distress”; from 60
to 72 a “Moderate Distress”; and >72 “No Distress”
category [13, 14].
The 12-Item Short-Form Health Survey (SF-12) pro-
vides a Physical Component Summary (PCS) and a
Mental Component Summary (MCS). The PCS and
Fig. 1 Cohort diagram of participants to the study enrolled for the
home and in-laboratory management pathways
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MCS are standardised to a mean of about 50 (range 0–
100), with a score above 50 representing better than
average function and below 50 poorer than average func-
tion [15, 16].
The Italian version of Epworth Sleepiness Scale (ESS)
[17, 18] was administered to assess daytime sleepiness. A
score > 10 suggests EDS.
Study procedure
Patients’ HRQoL was assessed at the first visit (T0), and
the morning after CPAP titration (T1). A portion of the
sample was included in previous studies [10, 11].
The study affected neither the patients’ diagnostic pro-
cedure and routine care nor the timing of CPAP titration.
After diagnosis, patients received counseling by a sleep
physician regarding the diagnostic results, basic informa-
tion on OSA, its effects on comorbid conditions and day-
time performance, the importance of treatment adherence
and the consequences of ineffective treatment.
Then, the staff identified the suitable mask and held a
session of education and training to CPAP therapy and
mask fitting. The duration of this phase was about
30 min. Subjects were allowed to choose to receive
CPAP titration at home or in the laboratory. Titration
was performed using auto-adjusting CPAP units (S9TM,
ResMed Ltd, Bella Vista, Australia) at patients’ home for
3 to 5 nights or in the sleep lab . Throughout the night
and the next morning, the staff on duty in the lab dealt
with any discomfort related to the CPAP treatment. The
pressure selected for CPAP treatment was the pressure
at which the participant spent 90% of the time with
apnea-hypopnea index (AHI) lower than 10 events/hour
[8]. Successful unattended titration of APAP require a
minimum of 1 night with at least 6 h of total recording,
and at least 5 h with a mean mask leak <0.4 l/s [9]. We
considered the home titration acceptable if it was carried
out ≥2 nights, its average duration was ≥ 4 h/night and
leaks were <24 l/min.
In order to explore whether, and to what extent, CPAP
titration affects patients’ HRQoL, an assistant psychologist
administered self-reported questionnaires in the same
order: ESS only at T0, and PGWBI, followed by SF-12 at
T0 and T1.
Statistical analysis
Data are reported as mean ± SD. The non-parametric
Wilcoxon test was used to assess differences between
genders, smoking, alcohol use, comorbidities, OSA se-
verity and between laboratory and home groups in terms
of characteristics and HRQoL scores. Questionnaires
mean differences between T0 and T1 were evaluated by
paired t-test. The Cohen’s d effect size (ES), for the two
paired samples (T0, T1), was estimated dividing the t
value of the paired t-test by the square root of the
number of pairs. Effects sizes show the magnitude of dif-
ferences observed [19].
Pearson’s chi-square was applied to assess differences
in “Distress category” between T0 and T1. Relationships
between age, BMI, AHI, Tsat90, ESS and HRQoL scores
changes (scores at T1 minus scores at T0) were identi-
fied through a linear regression analysis. A p < 0.05 was
considered significant. Statistical analysis was performed
by commercial software (JMP 8.0 SAS Institute Inc.).
Results
Sample characteristics and nocturnal sleep study results
for all subjects and by gender are shown in Table 1.
Male and female patients differed in age and body mass
index (BMI). In our sample, 47 subjects (22,9%) were
smokers, and 108 subjects (52,7%) had hypertension.
Table 2 shows PGWBI and SF-12 sample scores at T0
and T1. In the whole sample, at T0 mean question-
naires scores were worse than reference values (p <
0.0260) [13, 15]. At T1, PGWBI scores were improved
compared to T0, and Anxiety, Depression and Well-
Being PGWBI subscales became similar to reference
values. SF-12 showed an improvement for MCS, but
not for PCS. ES indicated medium levels of improve-
ment for PGWBI total score, and Anxiety, Depression,
Health and Vitality subscales. Linear regression analysis
between questionnaires changes (scores at T1 minus
scores at T0), and age, BMI, AHI, Tsat90 and ESS did
not show any significant relationship.
Characteristics of populations in terms of smoking,
alcohol use, comorbidities and analysis stratified by OSA
severity did not show any significant relationship with
HRQoL score changes.
Table 3 shows PGWBI and SF-12 scores for each gen-
der. Mean questionnaires scores were better for males
compared to females at both times (p < 0.0460), except
for Anxiety PGWBI subscale at T0. Females showed a
medium ES improvement in PGWBI total score and
Anxiety, Health and Vitality subscales, and SF-12 MCS.
Males improved all scores except for Self-control
PGWBI subscale and SF-12 PCS, with a medium ES on
PGWBI Total score and Anxiety, Depression and Health
subscales (Table 3).
Figure 2 shows sample distribution for PGWBI Total
score at both times, as reported in PGWBI Manual [13].
Category distribution was different between T0 and T1
(chi-square = 110.72; p < 0.0001), with an increase in
subjects with PGWBI Total score >72 after CPAP
titration.
Dividing the sample in laboratory and home CPAP titra-
tion pathways, the characteristics of both groups were
similar. Comparing PGWBI and SF-12 scores at T0 and
T1 separately for laboratory and home CPAP titration
pathways, we found differences between groups at T0 for
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Well-being (p = 0.0288) and Vitality (p = 0.0354) PGWBI
subscales, and for SF-12 MCS (p = 0.0464). At T1 HRQoL
scores of laboratory and home CPAP titration pathways,
were not different.
At T1, the home group improved in all scores except
one (SF-12 PCS), while laboratory group improved in
Anxiety, Depression and Health PGWBI subscales. ES
indicated medium changes for home group in PGWBI
total score, and Anxiety, Depression, Well-being, Health
and Vitality subscales, and in SF-12 MCS.
Discussion
The results of this study show that HRQoL among sub-
jects afferent to our sleep center for suspicion of OSA
was impaired at first visit. CPAP titration was followed
by a significant improvement in HRQoL as evaluated by
PGWBI and SF-12, irrespective of age, BMI, OSA sever-
ity, nocturnal hypoxia and EDS. Sample distribution for
PGWBI scores at T1 showed an increase of subjects with
the highest well-being. Males showed better scores than
females in both questionnaires at T0 and at T1. After
CPAP titration, patients receiving home and laboratory
CPAP titration pathways achieved similar scores in
HRQoL questionnaires. Home group improved in every
questionnaires subscale, except SF-12 PCS, while those
with laboratory CPAP titration showed a significant im-
provement only in Anxiety, Depression and Health
PGWBI subscales.
OSA is a very prevalent still largely under-diagnosed
disease that significantly impairs quality of life [3–5].
Many studies highlighted that untreated patients with
OSA have a worse quality of life when compared with
the general population [20]. Similarly to the present
study, other investigators have observed no correlation
between OSA severity and HRQoL, emphasizing that
the physiological parameters alone may not be the only
determinants of HRQoL [21, 22]. The consequences of
sleep-related breathing disorders on HRQoL may be
considered as a multifactorial phenomenon, including
not only sleep disruption, sleepiness and obesity, but
also mood and psychosocial factors, which are all impli-
cated in different aspects of physical and mental health
perception [23].
As far as we know, there are no studies that examine
perceived HRQoL variation immediately after CPAP
titration. Nevertheless, many studies have analyzed the
effect of 3–6 months of CPAP therapy on HRQoL,
pointing out a significant improvement [24]. In our
study, the improvement on perceived HRQoL is notice-
able immediately after CPAP titration. Besides, it is
possible to hypothesize that, after long-term CPAP use,
the change in HRQoL would be even more evident and
extended to more dimensions (for instance, those relating
to SF-12 PCS), not yet impacted after CPAP titration.
In our sample, males’ perceived HRQoL was better
than females’, and both genders showed an improvement
after CPAP titration. Male subjects reported a significant
improvement in SF-12 MCS and in all PGWBI subscales
except for Self-Control, while females improved only in
Table 1 Patients characteristics and nocturnal polygraphic results
Total Female Male
Subjects, No. 205 54 151
Age, yrs 56.7 ± 10.3 (25–79) 59.8 ± 7.8 (42–76) 55.6 ± 10.9* (25–79)
BMI, kg/m2 33.0 ± 6.4 (22.8–51.6) 35.8 ± 7.7 (22.8–51.6) 32.0 ± 5.6** (23.0–50.0)
AHI, n/h 47.8 ± 24.4 (6–118) 48.1 ± 29.0 (9–118) 47.6 ± 22.7 (6–101)
Mild, No. (%) 18 (8.8) 7 (13.0) 11 (7.3)
Moderate, No. (%) 40 (19.5) 11 (20.4) 29 (19.2)
Severe, No. (%) 147 (71.7) 36 (66.6) 111 (73.5)
TSat90, % 24.4 ± 23.9 (0–93.1) 29.2 ± 27.6 (0.1–93) 22.6 ± 22.3 (0–93.1)
ESS score 11.0 ± 5.0 (1–24) 10.9 ± 5.0 (2–22) 11.0 ± 5.1 (1–24)
Data are given as mean ± SD (range). BMI = body mass index; AHI = Apnea hypopnea index; Mild = AHI ≥5, but < 15per hour; Moderate = AHI ≥15, but < 30per
hour; Severe = AHI ≥30 per hour; TSat90 = percent study-time at less than 90% oxygen saturation; ESS = Epworth Sleepiness Scale; F = Female; M =Male
*p = 0.0131, **p = 0.0018 F vs M
Table 2 Health-related quality of life data by PGWBI and SF-12
T0 T1 ES
PGWBI 69.5 ± 16.8 74.7 ± 17.4* 0.45
Anxiety 15.7 ± 4.8 17.4 ± 4.7* 0.42
Depression 12.0 ± 2.6 12.6 ± 2.3* 0.30
Well-being 11.1 ± 3.9 11.9 ± 3.8** 0.25
Self-control 10.8 ± 3.0 11.1 ± 3.0† 0.14
Health 9.3 ± 2.8 10.1 ± 2.6* 0.37
Vitality 10.6 ± 3.8 11.6 ± 3.7* 0.31
SF-12 PCS 42.7 ± 9.8 43.2 ± 10.2 -
SF-12 MCS 44.8 ± 10.4 46.7 ± 10.6** 0.23
Data are given as mean ± SD. PGWBI = Psychological General Well-Being Index;
SF-12 = 12-Item Short-Form Health Survey; PCS = Physical Component Sum-
mary; MCS =Mental Component Summary; T0 = first time visit; T1 = after CPAP
titration; ES = Effect Size
*p < 0.0001, **p < 0.005, †p < 0.05 T0 vs T1
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total PGWBI score and Health and Vitality subscales.
However, adequately powered studies are necessary to
examine gender differences in OSA clinical manifesta-
tions and response to CPAP. Gender differences could
be explained by female characteristics such as greater
bodily attention, as well as social acceptance for females
to express distress [25]. Females in a healthy population
reported poorer well-being and had a higher symptom
complaint rate [13, 15]. Furthermore, other studies sug-
gest that females have more psychological morbidity and
a poorer HRQoL than men in association with OSA
[26], that may be due to differences in experience of
OSA, like insomnia, depression vs. sleepiness, irritability.
Another finding of the present study is that both
patients receiving home and laboratory CPAP titration
perceived an improvement in HRQoL. Similar results
were showed in previous reports that compared patients
HRQoL assessed before laboratory or home CPAP titra-
tion and at 1 or 3 months follow-up visit, finding no
statistical differences between groups [27–29].
Our results show that benefits on HRQoL perception
for home pathway are non-inferior to those with labora-
tory CPAP titration, underlining also some advantage for
home CPAP titration and suggesting that comfortable
environment may be useful to increase patients’ oppor-
tunity to experience CPAP benefits.
Many studies demonstrated that home unattended
diagnostic/therapeutic program is a practical strategy, as
effective as the laboratory attended evaluation, resulting
in similar functional outcomes and adherence to CPAP
Table 3 Health-related quality of life data by PGWBI and SF-12 for gender
Female (54) Male (151)
T0 T1 ES T0 T1 ES
PGWBI 61.7 ± 19.5 67.7 ± 19.1** 0.40 72.3 ± 14.9 77.2 ± 15.8* 0.48
Anxiety 14.4 ± 5.8 16.1 ± 5.0† 0.33 16.1 ± 4.4 17.8 ± 4.6* 0.46
Depression 11.3 ± 2.9 11.6 ± 2.8 - 12.2 ± 2.4 13.0 ± 2.0* 0.38
Well-being 9.3 ± 4.1 10.0 ± 3.9 - 11.8 ± 3.6 12.5 ± 3.6** 0.28
Self-control 9.3 ± 3.5 9.8 ± 3.5 - 11.3 ± 2.6 11.6 ± 2.7 -
Health 8.0 ± 2.9 9.4 ± 2.8** 0.51 9.7 ± 2.6 10.4 ± 2.5** 0.31
Vitality 9.3 ± 4.0 10.7 ± 4.1† 0.35 11.1 ± 3.5 12.0 ± 3.5** 0.29
SF-12 PCS 36.7 ± 9.4 38.0 ± 9.6 - 44.8 ± 9.0 45.0 ± 9.7 -
SF-12 MCS 40.7 ± 11.3 43.9 ± 10.9† 0.36 46.3 ± 10.3 47.7 ± 10.3† 0.18
Data are given as mean ± SD. PGWBI = Psychological General Well-Being Index; SF-12 = 12-Item Short-Form Health Survey; PCS = Physical Component Summary;
MCS =Mental Component Summary; T0 = first time visit; T1 = after CPAP titration; ES = Effect Size; F = Female; M =Male
*p < 0.0001, **p < 0.005, †p < 0.05 T0 vs T1
Fig. 2 Sample distribution for PGWBI Total before and after titration. T0 = first time visit; T1 = after CPAP titration. Higher scores indicate better
well-being. Chi-square = 110.72; p < 0.0001. At T0: 60 subjects had PGWBI <60; 51 subjects had PGWBI from 60 to 72; 94 subjects had PGWBI >72.
At T1: 40 subjects had PGWBI <60; 48 subjects had PGWBI from 60 to 72; 117 subjects had PGWBI >72
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treatment [7, 8, 28]. In addition, it has proved more
comfortable for patients, avoiding the “first-night effect”,
generally not present at home, that could induce vari-
ability in sleep architecture [30]. Moreover, CPAP ther-
apy needs more cooperation than just taking a pill.
Several studies have underlined the importance of the
impact of first feeling with CPAP use as significant pre-
dictor to future treatment adherence, suggesting that
benefits perceived after first night of CPAP titration are
relevant in determining CPAP adherence [30–32]. A
better information about OSA [33, 34], and a first
experience with CPAP in a comfortable environment
may increase confidence in health staff and compliance
to the CPAP treatment, and improve doctor-patient
relationship.
Our study has some limitations. One concerns the
difference in the number of days of CPAP titration be-
tween home and laboratory groups. However, our main
outcome was the immediate effect of CPAP and we
chose to compare a 3 to 5-night period of home titration
with a 1-night laboratory titration to guarantee the com-
fort for patients who were living far away from the sleep
laboratory and to compare the effects of two CPAP titra-
tion pathways, as performed routinely, in order to appre-
ciate differences, if any, between common methods of
patients management. Furthermore, subjects were allowed
to choose to receive CPAP titration at home or in the
laboratory, therefore, there may be an unmeasured self-
selection bias whereby subjects who chose to have home
titrations may have been more likely to have perceived
improvement in HRQoL. Another limitation was related to
the different size of males and females subgroups. Further
studies are needed to assess gender differences. Fur-
thermore, we used the SF-12, whereas using SF-36
could have potentially provided better discrimination.
However, PGWBI and SF-12 were administered to-
gether to guarantee a further extension of HRQoL
measures, avoiding an excessive and confusing num-
ber of items during administration.
Despite these limitations, the study provides evidence
that CPAP titration has an impact on perceived well-
being, and that HRQoL improves as soon as CPAP is
initiated. We can also address an important clinical
question about home CPAP titration benefits that are
not inferior to laboratory titration pathway.
Conclusions
In summary, this study shows that CPAP titration can lead
to a general increase in perceived well-being, regardless of
age, gender, BMI, AHI, TSat90 and EDS. Gender compari-
sons showed better perceived HRQoL with more subscales
improvements in males after CPAP titration. After CPAP
titration, regardless of home or laboratory pathway, there
was an improvement in perceived HRQoL. The first night
may improve the feeling to CPAP therapy, underlining
that development of innovative medical interventions in
comfortable home environment is effective to improve pa-
tients’ opportunity to adapt and experience CPAP benefits.
New studies are required to evaluate the influence of per-
ceived HRQoL after CPAP titration on the subsequent
adherence to CPAP treatment.
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